Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treatment option and further building on its differentiated LAI franchise and scientific leadership in complex neurological c ...

Core Viewpoint - Teva Pharmaceuticals reported Q4 and full-year 2025 results for UZEDY®, indicating strong sales performance and providing a positive outlook for 2026 [1] Group 1: Financial Performance - UZEDY® net sales for 2025 reached $191 million, with $55 million generated in the fourth quarter [1] - Teva's initial net sales outlook for UZEDY® in 2026 is projected to be between $250 million and $280 million [1] Group 2: Royalty Information - Medincell receives mid to high single-digit royalties on UZEDY® net sales [1] - Medincell is eligible for up to $105 million in royalties [1]